Labroots

Continuous Low-Dose Lenalidomide Delivery for Hematologic Malignancies: Preclinical to Phase 2 Insights

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...
The American Journal of Managed Care

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Personalized treatment approaches are crucial for older, frail, and high-risk multiple myeloma patients, focusing on dosing intensity rather than the number of drugs. The MAIA study showed significant ...
MedPage Today

Some Frail Myeloma Patients Can Quickly Wean Off Dexamethasone, Study Says

A dexamethasone-sparing regimen of daratumumab and lenalidomide was safe and effective in older, frail patients with newly diagnosed multiple myeloma. Among that select group of patients, ...
ascopubs.org

Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status ...
ascopubs.org

Carfilzomib or bortezomib with lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Long-term follow-up of the ECOG-ACRIN ...

Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses.
AOL

Does Medicare cover Revlimid?

Revlimid (lenalidomide) is a brand-name drug that doctors may prescribe to treat certain cancers of the blood. If a person has a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) ...